Veracyte (FRA:12V) Cyclically Adjusted Revenue per Share: €3.54 (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:12V Veracyte Inc FRA:12V
76 GF Score
Price €50.02
GF Value €33.90
Valuation Significantly Overvalued
! 7 Warning Signs
View Full Analysis

What is Veracyte Cyclically Adjusted Revenue per Share?

Veracyte FRA:12V +0.36% 76 Cyclically Adjusted Revenue per Share is €3.54 as of Mar. 2026. GuruFocus rates FRA:12V with a GF Score™ of 76/100 and a GF Value™ of €33.90 (Significantly Overvalued). The stock has 7 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

Veracyte's adjusted revenue per share for the three months ended in Mar. 2026 was €1.479. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is €3.54 for the trailing ten years ended in Mar. 2026.

During the past 12 months, Veracyte's average Cyclically Adjusted Revenue Growth Rate was 14.40% per year. During the past 3 years, the average Cyclically Adjusted Revenue Growth Rate was 14.10% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Revenue Growth Rate of Veracyte was 14.10% per year. The lowest was 14.10% per year. And the median was 14.10% per year.

As of today (2026-07-25), Veracyte's current stock price is €50.02. Veracyte's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2026 was €3.54. Veracyte's Cyclically Adjusted PS Ratio of today is 14.13.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Veracyte was 14.10. The lowest was 5.80. And the median was 8.48.


Veracyte  (FRA:12V) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Veracyte's Cyclically Adjusted PS Ratio of today is calculated as

Cyclically Adjusted PS Ratio=Share Price/Cyclically Adjusted Revenue per Share
=50.02/3.54
=14.13

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Veracyte was 14.10. The lowest was 5.80. And the median was 8.48.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


Veracyte Cyclically Adjusted Revenue per Share Related Terms


Veracyte Cyclically Adjusted Revenue per Share Historical Data

* Premium members only.

The historical data trend for Veracyte's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Veracyte Cyclically Adjusted Revenue per Share Chart

Veracyte Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 2.59 2.99 3.51 3.53

Veracyte Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 3.49 3.30 3.40 3.53 3.54

FRA:12V vs RDNT, SHC, BLLN: Cyclically Adjusted Revenue per Share Comparison

For the Diagnostics & Research subindustry, Veracyte's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Veracyte Cyclically Adjusted PS Ratio vs Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Veracyte's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Veracyte's Cyclically Adjusted PS Ratio falls into.


FRA:12V
76GF Score
Veracyte Inc FRA:12V
Cyclically Adjusted Revenue per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Veracyte Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Veracyte's adjusted Revenue per Share data for the three months ended in Mar. 2026 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=1.479/330.2130*330.2130
=1.479

Current CPI (Mar. 2026) = 330.2130.

Veracyte Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201606 0.469 241.018 0.643
201609 0.594 241.428 0.812
201612 0.513 241.432 0.702
201703 0.454 243.801 0.615
201706 0.484 244.955 0.652
201709 0.433 246.819 0.579
201712 0.486 246.524 0.651
201803 0.474 249.554 0.627
201806 0.568 251.989 0.744
201809 0.521 252.439 0.682
201812 0.555 251.233 0.729
201903 0.635 254.202 0.825
201906 0.585 256.143 0.754
201909 0.579 256.759 0.745
201912 0.545 256.974 0.700
202003 0.566 258.115 0.724
202006 0.366 257.797 0.469
202009 0.482 260.280 0.612
202012 0.489 260.474 0.620
202103 0.487 264.877 0.607
202106 0.679 271.696 0.825
202109 0.736 274.310 0.886
202112 0.838 278.802 0.993
202203 0.864 287.504 0.992
202206 0.964 296.311 1.074
202209 1.065 296.808 1.185
202212 1.055 296.797 1.174
202303 1.067 301.836 1.167
202306 1.150 305.109 1.245
202309 1.160 307.789 1.245
202312 1.232 306.746 1.326
202403 1.192 312.332 1.260
202406 1.378 314.175 1.448
202409 1.330 315.301 1.393
202412 1.405 315.605 1.470
202503 1.323 319.799 1.366
202506 1.440 322.561 1.474
202509 1.410 324.800 1.433
202512 1.457 324.054 1.485
202603 1.479 330.213 1.479

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

What does a Cyclically Adjusted Revenue per Share of €3.54 mean?
Veracyte (FRA:12V) has a Cyclically Adjusted Revenue per Share of €3.54 as of Mar. 2026. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Veracyte and its competitors.
Is Veracyte's Cyclically Adjusted Revenue per Share too high?
Veracyte's current Cyclically Adjusted Revenue per Share is €3.54. Overall, Veracyte has a GF Score™ of 76/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Veracyte's Cyclically Adjusted Revenue per Share compare to RDNT and SHC?
Veracyte's Cyclically Adjusted Revenue per Share of €3.54 can be compared against companies in the Medical Diagnostics & Research industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Revenue per Share for a Medical Diagnostics & Research company?
A good Cyclically Adjusted Revenue per Share depends on the Medical Diagnostics & Research industry context. However, Cyclically Adjusted Revenue per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Revenue per Share mean?
A high Cyclically Adjusted Revenue per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Veracyte and its competitors. Veracyte's current Cyclically Adjusted Revenue per Share is €3.54. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Veracyte stock overvalued right now?
Based on GuruFocus' analysis, Veracyte (FRA:12V) is currently considered Significantly Overvalued. The stock's GF Value™ is €33.90, compared to a current price of €50.02 — trading 47.6% above its estimated fair value. The current Cyclically Adjusted Revenue per Share is €3.54. Veracyte's overall GF Score™ is 76/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Revenue per Share calculated?
Cyclically Adjusted Revenue per Share is calculated from a company's financial statements. For Veracyte (FRA:12V), the current Cyclically Adjusted Revenue per Share is €3.54 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Veracyte (FRA:12V) Overvalued in 2026?

Based on GuruFocus' analysis, Veracyte stock appears to be overvalued. The current stock price of €50.02 is trading 47.6% above its estimated GF Value™ of €33.90. GuruFocus considers Veracyte to be Significantly Overvalued.

Key valuation signals for FRA:12V:

  • Cyclically Adjusted Revenue per Share: €3.54
  • GF Value™: €33.90 vs. price of €50.02 (47.6% above fair value)
  • GF Score™: 76/100 with 7 warning signs

No single metric tells the full story. See the FRA:12V stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Veracyte Business Description

Other Exchanges VCYT:USA12V:Germany
Address 6000 Shoreline Court, Suite 300, South San Francisco, CA, USA, 94080
Veracyte Inc is a genomic diagnostics company. The group empowers clinicians with the insights necessary to guide and assure patients at pivotal moments in the race to diagnose and treat cancer. It offers tests for prostate cancer (Decipher Prostate), thyroid cancer (Afirma), breast cancer (Prosigna), and bladder cancer (Decipher Bladder).
76GF Score

Get the complete analysis for FRA:12V

Cyclically Adjusted Revenue per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€50.02
Price
€33.90
GF Value